Earlier, FDA Approved Marketing of RMS Subcutaneous Needle Sets

Repro-Med Systems

announced today that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets. The needle sets are intended for the delivery of medication to subcutaneous tissue. The needle sets have previously been approved and available for use by patients in Canada and Europe. Repro-Med Systems, Inc. utilizes the name RMS Medical Products. "The FDA's approval allows patients here in the U.S., where our products are manufactured, to enjoy the benefits realized currently by many patients overseas," said Andrew I. Sealfon, president of the company, based in Chester, NY. "Although we use a needle which is smaller in gauge than many needles being used for subcutaneous administration of certain drugs, our design results in flow rates comparable to, or better than, the flow rates of the larger needles. This can result in less pain and discomfort for the patient, less insertion difficulty for the patient and medical personnel, and shorter infusion times," Sealfon added. The needle sets are an ideal companion for RMS Medical Products' FREEDOM60® Syringe Infusion System, which has enhanced the lifestyle of numerous patients requiring regular drug infusions due to its portability and ease of use. FREEDOM60® enjoys widespread use by ambulatory patients at home as well as those in healthcare facilities. "Even though the RMS Subcutaneous Needle Sets provide advanced fluidics, the pricing will be highly competitive, just as FREEDOM60® has been in the infusion pump market," Sealfon said.